NEW YORK, October 26, 2016 /PRNewswire/ --
Stock-Callers.com is closely reviewing the most recent performances of four major
players in the Drug Manufacturers space: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE:
MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). These companies belong
to the Healthcare sector which was little changed from its mid-day declines on Tuesday,
October 25, 2016, with the NYSE Health Care Index slipping about 0.5%, and shares of
health care companies in the S&P 500 declining 0.2% as a group. Learn more about these
stocks by accessing their free research reports at:
New York headquartered Pfizer Inc.'s shares rose 0.47% and finished Tuesday's trading
session at $32.28. A total volume of 19.32 million shares was traded, which was above
their three months average volume of 18.96 million shares. Since the start of this year,
the stock has advanced 2.76%. The Company's shares are trading below their 200-day moving
average by 1.43%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and
sells healthcare products worldwide, have a Relative Strength Index (RSI) of 32.20.
On October 13th, 2016, research firm Jefferies downgraded the Company's stock rating
from 'Buy' to 'Hold'.
On October 21st, 2016, Astellas Pharma Inc. and Pfizer announced the U.S. Food and
Drug Administration approved a supplemental New Drug Application to update the U.S.
product labeling for XTANDI(R) (enzalutamide) capsules to include new clinical data versus
bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic
progression-free survival in patients with metastatic castration-resistant prostate cancer
who were treated with enzalutamide compared to patients who were treated with
bicalutamide. Free research report on PFE is available at:
On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a
trading volume of 15.12 million shares, which was above their three months average volume
of 10.25 million shares. The stock ended the session 1.98% higher at $61.95. The Company's
shares have gained 6.49% in the previous three months and 20.15% on an YTD basis. The
stock is trading 10.39% above its 200-day moving average. Furthermore, shares of Merck,
which provides health care solutions worldwide, have an RSI of 48.91.
On October 13th, 2016, research firm Bank of America/ Merrill upgraded the Company's
stock rating from 'Neutral' to 'Buy'.
On October 25th, 2016, Merck reported that worldwide sales were $10.5 billion for Q3
2016, an increase of 5% compared with Q3 2015, including a 1% negative impact from foreign
exchange. For Q3 2016, GAAP EPS assuming dilution were $0.78 compared to EPS of $0.64 in
Q3 2015. Q3 2016 pharmaceutical sales increased 6% to $9.4 billion. The complimentary
research report on MRK can be downloaded at:
Shares in Illinois-based AbbVie Inc. closed the day at $61.55, up 0.70%. The stock
recorded a trading volume of 6.41 million shares, which was higher than its three months
average volume of 6.16 million shares. The Company's shares have gained 7.92% on an YTD
basis, and are trading 3.07% above their 200-day moving average. Additionally, shares of
AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products
worldwide, have an RSI of 45.56.
On October 18th, 2016, research firm Leerink Partners initiated a 'Market Perform'
rating on the Company's stock, issuing a target price of $70 per share.
On October 19th, 2016, AbbVie in cooperation with Neurocrine Biosciences, Inc.
announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating
the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis.
The data demonstrate that, compared to placebo at month three and month six, patients
treated with Elagolix reported statistically significant reductions in scores for
menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by
the Daily Assessment of Endometriosis Pain scale. Visit us today and access our complete
research report on ABBV at:
Johnson & Johnson
At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson &
Johnson ended 0.31% higher at $113.96 and with a total trading volume of 5.59 million
shares. The stock has advanced 13.29% since the start of this year. The Company's shares
are trading above their 200-day moving average by 1.18%. Furthermore, shares of Johnson &
Johnson, which together with its subsidiaries, researches and develops, manufactures, and
sells various products in the health care field worldwide, have an RSI of 34.94.
On October 19th, 2016, research firm UBS reiterated a 'Buy' rating on the Company's
stock with an increase of the target price from $137 a share to $144 a share.
On October 20th, 2016, Johnson & Johnson' Board of Directors declared a cash dividend
for Q4 2016 of $0.80 per share. The dividend is payable on December 6th, 2016 to
shareholders of record at the close of business on November 22nd, 2016. Get free access to
your research report on JNJ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering equities listed on NYSE
and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One
department produces non-sponsored analyst certified content generally in the form of press
releases, articles and reports covering equities listed on NYSE and NASDAQ and the other
produces sponsored content (in most cases not reviewed by a registered analyst), which
typically consists of compensated investment newsletters, articles and reports covering
listed stocks and micro-caps. Such sponsored content is outside the scope of procedures
SC has not been compensated; directly or indirectly; for producing or publishing this
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author")
and is fact checked and reviewed by a third party research service company (the
"Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA(R)
charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on
publicly available information which is believed to be reliable. Content is researched,
written and reviewed on a reasonable-effort basis. The Reviewer has not performed any
independent investigations or forensic audits to validate the information herein. The
Reviewer has only independently reviewed the information provided by the Author according
to the procedures outlined by SC. SC is not entitled to veto or interfere in the
application of such procedures by the third-party research service company to the articles,
documents or reports, as the case may be. Unless otherwise noted, any content outside of
this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be
occasioned at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted whatsoever for any direct, indirect or consequential loss arising
from the use of this document. SC, the Author, and the Reviewer expressly disclaim any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Additionally, SC, the Author,
and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an
offer to buy or sell the securities mentioned or discussed, and is to be used for
informational purposes only. Please read all associated disclosures and disclaimers in
full before investing. Neither SC nor any party affiliated with us is a registered
investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To
download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company
we are covering and wish to no longer feature on our coverage list contact us via
email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA
SOURCE Chelmsford Park SA